Protective role of heat shock proteins in Parkinson's disease

Neurodegenerative Diseases

Volumn 8, Issue 4, 2011, Pages 155-168

  Aridon, Paolo ^a   Geraci, Fabiana ^a   Turturici, Giuseppina ^a   D'amelio, Marco ^a   Savettieri, Giovanni ^a   Sconzo, Gabriella ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Heat shock protein; HSP70; HSP90; Parkinson disease; Parkinson's disease associated genes

Indexed keywords

HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90;

APOPTOSIS; BRAIN NERVE CELL; CELL ORGANELLE; CELL SURVIVAL; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW;

ANIMALS; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PARKINSON DISEASE;

EID: 79955830308     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000321548     Document Type: Review

References (123)

1. Lebouvier T, Chaumette T, Paillusson S, Duyckaerts C, Bruley des Varannes S, Neunlist M, Derkinderen P: The second brain and Parkinson's disease. Eur J Neurosci 2009; 30: 735-741.
2. Gasser T: Overview of the genetics of parkinsonism. Adv Neurol 2003; 91: 143-152.
3. Hatano T, Kubo S, Sato S, Hattori N: Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem 2009; 111: 1075-1093.
4. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C: Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 2010; 31: 763-780.
5. Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57-87. (Pubitemid 41098899)
6. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ: Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001; 293: 263-269. (Pubitemid 32694735)
7. Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu PP, Stadler J, Chandran J, Klinefelter GR, Blackstone C, Cookson MR: L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitinproteasome system. J Biol Chem 2003; 278: 36588-36595. (Pubitemid 37139990)
8. Sherman MY, Goldberg AL: Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001; 29: 15-32. (Pubitemid 32108719)
9. Giasson BI, Lee VM: Are ubiquitination pathways central to Parkinson's disease? Cell 2003; 114: 1-8. (Pubitemid 36859837)
10. De Maio A: Heat shock proteins: facts, thoughts, and dreams. Shock 1999; 11: 1-12.
11. Multhoff G: Heat shock protein 70 (Hsp70): membrane location, export and immunological relevance. Methods 2007; 43: 229-237. (Pubitemid 47499077)
12. Hartl FU, Hayer-Hartl M: Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002; 295: 1852-1858. (Pubitemid 34214115)
13. Slepenkov SV, Witt SN: The unfolding story of the Escherichia coli Hsp70 DnaK: is DnaK a holdase or an unfoldase?. Mol Microbiol 2002; 45: 1197-1206. (Pubitemid 35015345)
14. Bukau B, Weissman J, Horwich A: Molecular chaperones and protein quality control. Cell 2006; 125: 443-451.
15. Anckar J, Sistonen L: Heat shock factor 1 as a coordinator of stress and developmental pathways. Adv Exp Med Biol 2007; 594: 78-88.
16. Fargnoli J, Kunisada T, Fornace AJ Jr, Schneider EL, Holbrook NJ: Decreased expression of heat shock protein 70 mRNA and protein after heat treatment in cells of aged rats. Proc Natl Acad Sci USA 1990; 87: 846-850. (Pubitemid 20051468)
17. Sóti C, Csermely P: Molecular chaperones and the aging process. Biogerontology 2000; 1: 225-233.
18. Schultz C, Dick EJ, Cox AB, Hubbard GB, Braak E, Braak H: Expression of stress proteins alpha B-crystallin, ubiquitin, and hsp27 in pallido-nigral spheroids of aged rhesus monkeys. Neurobiol Aging 2001; 22: 677-682. (Pubitemid 32607752)
19. Walters TJ, Ryan KL, Mason PA: Regional distribution of Hsp70 in the CNS of young and old food-restricted rats following hyperthermia. Brain Res Bull 2001; 55: 367-374. (Pubitemid 32727896)
20. Moro F, Fernandez-Saiz V, Slutsky O, Azem A, Muga A: Conformational properties of bacterial DnaK and yeast mitochondrial Hsp70. Role of the divergent C-terminal alpha-helical subdomain. FEBS J 2005; 272: 3184-3196. (Pubitemid 40904703)
21. Bukau B, Horwich AL: The Hsp70 and Hsp60 chaperone machines. Cell 1998; 92: 351-366. (Pubitemid 28093013)
22. Flaherty KM, McKay DB, Kabsch W, Holmes KC: Similarity of the three-dimensional structures of actin and the ATPase fragment of a 70-kDa heat shock cognate protein. Proc Natl Acad Sci USA 1991; 88: 5041-5045. (Pubitemid 21914679)
23. Zhu X, Zhao X, Burkholder WF, Gragerov A, Ogata CM, Gottesman ME, Hendrickson WA: Structural analysis of substrate binding by the molecular chaperone DnaK. Science 1996; 272: 1606-1614. (Pubitemid 26200017)
24. Csermely P, Schnaider T, Soti C, Prohászka Z, Nardai G: The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998; 79: 129-168. (Pubitemid 28380440)
25. Pearl LH, Prodromou C, Workman P: The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410: 439-453. (Pubitemid 351429015)
26. Pratt WB, Morishima Y, Osawa Y: The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 2008; 283: 22885-22889.
27. Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A, Houry WA: Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005; 120: 715-727. (Pubitemid 40343082)
28. McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J: Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 2007; 131: 121-135. (Pubitemid 47498528)
29. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, de-Billy E, Salmons J, Walton M, Burlingame A, Waterfield M, Workman P: Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007; 67: 3239-3253. (Pubitemid 46724862)
30. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO: The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 2000; 275: 3305-3312. (Pubitemid 30083032)
31. Sreedhar AS, Kalmár E, Csermely P, Shen YF: Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004; 562: 11-15. (Pubitemid 38388440)
32. Ni M, Lee AS: ER chaperones in mammalian development and human diseases. FEBS Lett 2007; 581: 3641-3651. (Pubitemid 47082516)
33. Picard D: Heat-shock protein 90, a chaperone for folding and regulation: Cell Mol Life Sci 2002; 59: 1640-1648. (Pubitemid 35346967)
34. Sullivan W, Stensgard B, Caucutt G, Bartha B, McMahon N, Alnemri ES, Litwack G, Toft D: Nucleotides and two functional states of hsp90. J Biol Chem 1997; 272: 8007-8012. (Pubitemid 27137365)
35. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL: Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001; 47: 291-302. (Pubitemid 32640768)
36. Neckers L: Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 2002; 8: 962-966. (Pubitemid 34517628)
37. McClellan AJ, Scott MD, Frydman J: Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 2005; 121: 739-748. (Pubitemid 40797596)
38. Felts SJ, Toft DO: p23, a simple protein with complex activities. Cell Stress Chaperones 2003; 8: 108-113. (Pubitemid 36993176)
39. Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996; 271: 22796-22801. (Pubitemid 26304727)
40. Bonvini P, Dalla Rosa H, Vignes N, Rosolen A: Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 2004; 64: 3256-3264. (Pubitemid 38581430)
41. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS Jr, Hutton M, Burrows F, Petrucelli L: The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007; 117: 648-658. (Pubitemid 46348523)
42. Taylor DM, Tradewell ML, Minotti S, Durham HD: Characterizing the role of Hsp90 in production of heat shock proteins in motor neurons reveals a suppressive effect of wildtype Hsf1. Cell Stress Chaperones 2007; 12: 151-162. (Pubitemid 350224164)
43. Beal MF: Experimental models of Parkinson's disease. Nat Rev Neurosci 2001; 2: 325-334.
44. Dawson T, Mandir A, Lee M: Animal models of PD: pieces of the same puzzle? Neuron 2002; 35: 219-222. (Pubitemid 34876725)
45. Betarbet R, Sherer TB, Greenamyre JT: Animal models of Parkinson's disease. Bioessays 2002; 24: 308-318. (Pubitemid 34305686)
46. Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909. (Pubitemid 37130207)
47. Przedborski S, Vila M: The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci 2003; 991: 189-198. (Pubitemid 36793814)
48. Dong Z, Wolfer DP, Lipp HP, Bueler H: Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther 2005; 11: 80-88. (Pubitemid 40012001)
49. Nagel F, Falkenburger BH, Tönges L, Kowsky S, Pöppelmeyer C, Schulz JB, Bähr M, Dietz GP: Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem 2008; 105: 853-864. (Pubitemid 351562740)
50. Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, Montine TJ, Montine KS, Aebersold RH, Zhang J: Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem 2004; 279: 39155-39164. (Pubitemid 39296079)
51. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469-475.
52. Gurbuxani S, Schmitt E, Cande C, Parcellier A, Hammann A, Daugas E, Kouranti I, Spahr C, Pance A, Kroemer G, Garrido C: Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene 2003; 22: 6669-6678. (Pubitemid 37372207)
53. Jin J, Hulette C, Wang Y, Zhang T, Pan C, Wadhwa R, Zhang J: Proteomic identification of a stress protein, mortalin/mthsp70/ GRP75: relevance to Parkinson disease. Mol Cell Proteomics 2006; 5: 1193-1204. (Pubitemid 44103391)
54. Van Laar VS, Dukes AA, Cascio M, Hastings TG: Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis 2008; 29: 477-489.
55. De Mena L, Coto E, Sanchez-Ferrero E, Ribacoba R, Guisasola LM, Salvador C, Blazquez M, Alvarez V: Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. J Neural Transm 2009; 116: 1289-1293.
56. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR: Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 2007; 104: 955-960. (Pubitemid 46154718)
57. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM: Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002; 295: 865-868. (Pubitemid 34118369)
58. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ: Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 2004; 279: 25497-25502. (Pubitemid 38756808)
59. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN: Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol Biol 2005; 351: 1081-1100. (Pubitemid 41133454)
60. Eliezer D, Kutluay E, Bussell R Jr, Browne G: Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 2001; 307: 1061-1073. (Pubitemid 33029953)
61. Li J, Uversky VN, Fink AL: Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alphasynuclein. Biochemistry 2001; 40: 11604-11613. (Pubitemid 32911305)
62. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA: Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002; 8: 600-606. (Pubitemid 34633438)
63. Huang C, Cheng H, Hao S, Zhou H, Zhang X, Gao J, Sun QH, Hu H, Wang CC: Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates. J Mol Biol 2006; 364: 323-336. (Pubitemid 44717537)
64. Klucken J, Shin Y, Hyman BT, McLean PJ: A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochem Biophys Res Commun 2004; 325: 367-373. (Pubitemid 39441201)
65. Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL: Induction of neuronal death by alpha-synuclein. Eur J Neurosci 2000; 12: 3073-3077.
66. Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M: Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res 2001; 65: 432-438. (Pubitemid 32831396)
67. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, Dawson VL, Dawson TM, Ross CA: Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria- dependent apoptosis. Hum Mol Genet 2001; 10: 919-926. (Pubitemid 32401408)
68. Uryu K, Richter-Landsberg C, Welch W, Sun E, Goldbaum O, Norris EH, Pham CT, Yazawa I, Hilburger K, Micsenyi M, Giasson BI, Bonini NM, Lee VM, Trojanowski JQ: Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am J Pathol 2006; 168: 947-961. (Pubitemid 43327747)
69. Falsone SF, Kungl AJ, Rek A, Cappai R, Zangger K: The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. J Biol Chem 2009; 284: 31190-31199.
70. Auluck PK, Bonini NM: Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 2002; 8: 1185-1186. (Pubitemid 35373534)
71. Liu J, Zhou Y, Wang Y, Fong H, Murray TM, Zhang J: Identification of proteins involved in microglial endocytosis of alpha-synuclein. J Proteome Res 2007; 6: 3614-3627. (Pubitemid 47522751)
72. Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R, Chen S, Zhang J: Rab11a and HSP90 regulate recycling of extracellular alphasynuclein. J Neurosci 2009; 29: 1480-1485.
73. Hermeking H, Benzinger A: 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 2006; 16: 183-192. (Pubitemid 43810261)
74. Fu H, Subramanian RR, Masters SC: 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000; 40: 617-647. (Pubitemid 30340695)
75. Kawamoto Y, Akiguchi I, Nakamura S, Honjyo Y, Shibasaki H, Budka H: 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J Neuropathol Exp Neurol 2002; 61: 245-253. (Pubitemid 34212599)
76. Ubl A, Berg D, Holzmann C, Krüger R, Berger K, Arzberger T, Bornemann A, Riess O: 14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3 eta. Brain Res Mol Brain Res 2002; 108: 33-39. (Pubitemid 35447962)
77. Aitken A: 14-3-3 proteins: a historic overview. Semin Cancer Biol 2006; 16: 162-172. (Pubitemid 43796128)
78. Shirakashi Y, Kawamoto Y, Tomimoto H, Takahashi R, Ihara M: α -Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. Acta Neuropathol 2006; 112: 681-689. (Pubitemid 44615029)
79. Conway KA, Harper JD, Lansbury PT: Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998; 4: 1318-1320. (Pubitemid 28512115)
80. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr: Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000; 97: 571-576. (Pubitemid 30070350)
81. Choi HS, Lee SH, Kim SY, An JJ, Hwang SI, Kim DW, Yoo KY, Won MH, Kang TC, Kwon HJ, Kang JH, Cho SW, Kwon OS, Choi JH, Park J, Eum WS, Choi SY: Transduced Tatalpha-synuclein protects against oxidative stress in vitro and in vivo. J Biochem Mol Biol 2006; 39: 253-262. (Pubitemid 43854539)
82. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR: LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007; 405: 307-317. (Pubitemid 47075166)
83. Dächsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, Bailey RM, Hines JH, Szutu J, Madden B, Petrucelli L, Farrer MJ: Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord 2007; 13: 382-385. (Pubitemid 47449755)
84. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, Cai H: The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 2008; 28: 3384-3391. (Pubitemid 351469333)
85. Deng H, Dodson MW, Huang H, Guo M: The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 2008; 105: 14503-14508.
86. Poole AC, Thomas RE, Andrews LA, Mc-Bride HM, Whitworth AJ, Pallanck LJ: The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 2008; 105: 1638-1643. (Pubitemid 351346567)
87. Park J, Lee G, Chung J: The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem Biophys Res Commun 2009; 378: 518-523.
88. Narendra D, Tanaka A, Suen DF, Youle RJ: Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183: 795-803.
89. Narendra D, Tanaka A, Suen DF, Youle RJ: Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 2009; 5: 706-708.
90. Mata IF, Lockhart PJ, Farrer MJ: Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 2004; 13:R127-R133. (Pubitemid 38443806)
91. Johnston JA, Ward CL, Kopito RR: Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143: 1883-1898. (Pubitemid 29022611)
92. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN, Thomas PJ: Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 1999; 145: 481-490. (Pubitemid 29215713)
93. Kopito RR: Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10: 524-530.
94. Winklhofer KF, Henn IH, Kay-Jackson PC, Heller U, Tatzelt J: Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J Biol Chem 2003; 278: 47199-47208. (Pubitemid 37452306)
95. Imai Y, Soda M, Hatakeyama S, Akagi T, Hashikawa T, Nakayama KI, Takahashi R: CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell 2002; 10: 55-67. (Pubitemid 34876562)
96. Moore DJ, West AB, Dikeman DA, Dawson VL, Dawson TM: Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem 2008; 105: 1806-1819. (Pubitemid 351678490)
97. Liu M, Aneja R, Sun X, Xie S, Wang H, Wu X, Dong JT, Li M, Joshi HC, Zhou J: Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase. J Biol Chem 2008; 283: 35783-35788.
98. Kalia SK, Lee S, Smith PD, Liu L, Crocker SJ, Thorarinsdottir TE, Glover JR, Fon EA, Park DS, Lozano AM: BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 2004; 44: 931-945. (Pubitemid 39643090)
99. Tao X, Tong L: Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease. J Biol Chem 2003; 278: 31372-31379. (Pubitemid 36994657)
100. Honbou K, Suzuki NN, Horiuchi M, Niki T, Taira T, Ariga H, Inagaki F: The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. J Biol Chem 2003; 278: 31380-31384. (Pubitemid 36994658)
101. Wilson MA, Collins JL, Hod Y, Ringe D, Petsko GA: The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc Natl Acad Sci USA 2003; 100: 9256-9261. (Pubitemid 37033916)
102. Huai Q, Sun Y, Wang H, Chin LS, Li L, Robinson H, Ke H: Crystal structure of DJ-1/RS and implication on familial Parkinson's disease. FEBS Lett 2003; 549: 171-175. (Pubitemid 36959865)
103. Lee SJ, Kim SJ, Kim IK, Ko J, Jeong CS, Kim GH, Park C, Kang SO, Suh PG, Lee HS, Cha SS: Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain. J Biol Chem 2003; 278: 44552-44559. (Pubitemid 37377208)
104. Olzmann JA, Brown K, Wilkinson KD, Rees HD, Huai Q, Ke H, Levey AI, Li L, Chin LS: Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem 2004; 279: 8506-8515. (Pubitemid 38294744)
105. Zhou W, Freed CR: DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 2005; 280: 43150-43158. (Pubitemid 43049281)
106. Batelli S, Albani D, Rametta R, Polito L, Prato F, Pesaresi M, Negro A, Forloni G: DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS One 2008; 3:e1884.
107. Li HM, Niki T, Taira T, Iguchi-Ariga SM, Ariga H: Association of DJ-1 with chaperones and enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress. Free Radic Res 2005; 39: 1091-1099. (Pubitemid 41358563)
108. Moore DJ, Zhang L, Troncoso J, Lee MK, Hattori N, Mizuno Y, Dawson TM, Dawson VL: Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet 2005; 14: 71-84. (Pubitemid 40123464)
109. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr: The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002;111: 209-218. (Pubitemid 35292441)
110. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O: Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 2002; 326: 155-158. (Pubitemid 34722448)
111. Kabuta T, Furuta A, Aoki S, Furuta K, Wada K: Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem 2008; 283: 23731-23738.
112. Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA: UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem 2004; 90: 379-391. (Pubitemid 38938224)
113. Pridgeon JW, Olzmann JA, Chin LS, Li L: PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007; 5:e172.
114. Moriwaki Y, Kim YJ, Ido Y, Misawa H, Kawashima K, Endo S, Takahashi R: L347P PINK1 mutant that fails to bind to Hsp90/ Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner. Neurosci Res 2008; 61: 43-48.
115. Lin W, Kang UJ: Characterization of PINK1 processing, stability, and subcellular localization. J Neurochem 2008; 106: 464-474. (Pubitemid 351840220)
116. DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH: PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet 2002; 70: 1089-1095. (Pubitemid 34450562)
117. Mao XY, Burgunder JM, Zhang ZJ, Chang XL, Peng R, Burgunder JM, Yang Y, Wang YC, Li T, Zhang ZJ: ATP13A2 G2236A variant is rare in patients with early-onset Parkinson's disease and familial Parkinson's disease from Mainland China. Parkinsonism Relat Disord 2010; 16: 235-236.
118. Haugarvoll K, Toft M, Skipper L, Heckman MG, Crook JE, Soto A, Ross OA, Hulihan MM, Kachergus JM, Sando SB, White LR, Lynch T, Gibson JM, Uitti RJ, Wszolek ZK, Aasly JO, Farrer MJ: Fine-mapping and candidate gene investigation within the PARK10 locus. Eur J Hum Genet 2009; 17: 336-343.
119. Wang L, Guo JF, Zhang WW, Xu Q, Zuo X, Shi CH, Luo LZ, Liu J, Hu L, Hu YC, She L, Jiang H, Yan XX, Xia K, Pan Q, Tang BS: Novel GIGYF2 gene variants in patients with Parkinson's disease in Chinese population. Neurosci Lett 2010; 473: 131-135.
120. Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group: Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet 2003; 12: 2599-2608. (Pubitemid 37304683)
121. Dagda RK, Chu CT: Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/ HtrA2 interact to maintain mitochondrial homeostasis. J Bioenerg Biomembr 2009; 41: 473-479.
122. Tan EK, Ho P, Tan L, Prakash KM, Zhao Y: PLA2G6 mutations and Parkinson's disease. Ann Neurol 2010; 67: 148.
123. Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, Szczerbinska A, Zhao T, Dubbel-Hulsman LO, Wouters CH, de Graaff E, Oyen WJ, Simons EJ, Breedveld GJ, Oostra BA, Horstink MW, Bonifati V: FBXO7 mutations cause autosomal recessive, early-onset parkinsonianpyramidal syndrome. Neurology 2009; 72: 240-245.